ANL (Adlai Nortye) Other Stockholders Equity: $21.59 Mil (As of Dec. 2025)


What is Adlai Nortye Other Stockholders Equity?

Adlai Nortye ANL -4.86% Other Stockholders Equity is $21.59 Mil as of Dec. 2025. The stock has 7 warning signs investors should review.

Adlai Nortye's Other Stockholders Equity for the quarter that ended in Dec. 2025 was $21.59 Mil.

Adlai Nortye's quarterly Other Stockholders Equity increased from Dec. 2024 ($20.31 Mil) to Jun. 2025 ($20.84 Mil) and increased from Jun. 2025 ($20.84 Mil) to Dec. 2025 ($21.59 Mil).

Adlai Nortye's annual Other Stockholders Equity increased from Dec. 2023 ($18.02 Mil) to Dec. 2024 ($20.31 Mil) and increased from Dec. 2024 ($20.31 Mil) to Dec. 2025 ($21.59 Mil).

Adlai Nortye Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Adlai Nortye's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adlai Nortye Other Stockholders Equity Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
7.61 13.69 18.02 20.31 21.59

Adlai Nortye Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only 18.02 19.69 20.31 20.84 21.59

Adlai Nortye Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $21.59 Mil mean?
Adlai Nortye (ANL) has a Other Stockholders Equity of $21.59 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Adlai Nortye and its competitors.
Is Adlai Nortye's Other Stockholders Equity too high?
Adlai Nortye's current Other Stockholders Equity is $21.59 Mil.
How does Adlai Nortye's Other Stockholders Equity compare to OMER and PRME?
Adlai Nortye's Other Stockholders Equity of $21.59 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Adlai Nortye and its competitors. Adlai Nortye's current Other Stockholders Equity is $21.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current Other Stockholders Equity of $21.59 Mil. The current Other Stockholders Equity is $21.59 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Adlai Nortye (ANL), the current Other Stockholders Equity is $21.59 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adlai Nortye Business Description

Other Exchanges N2U0:Germany
Address 685 US Highway 1, New Jersey Biotechnology Development Center, 2nd Floor, North Brunswick, NJ, USA, 08902
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.